These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32349117)

  • 1. One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia.
    Xia L; Liu L; Hong X; Wang D; Wei G; Wang J; Zhou H; Xu H; Tian Y; Dai Q; Wu HE; Chang C; Wang L; Kosten TR; Zhang XY
    Neuropsychopharmacology; 2020 Jul; 45(8):1362-1368. PubMed ID: 32349117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.
    Zhang XY; Liu L; Liu S; Hong X; Chen DC; Xiu MH; Yang FD; Zhang Z; Zhang X; Kosten TA; Kosten TR
    Am J Psychiatry; 2012 Sep; 169(9):974-81. PubMed ID: 22952075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia.
    Shiina A; Shirayama Y; Niitsu T; Hashimoto T; Yoshida T; Hasegawa T; Haraguchi T; Kanahara N; Shiraishi T; Fujisaki M; Fukami G; Nakazato M; Iyo M; Hashimoto K
    Ann Gen Psychiatry; 2010 Jun; 9():27. PubMed ID: 20573264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers.
    Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
    J Psychopharmacol; 2019 Jun; 33(6):688-699. PubMed ID: 30920339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining CDP-choline and galantamine, an optimized α7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia.
    Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
    Int J Psychophysiol; 2019 Nov; 145():70-82. PubMed ID: 30790597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
    Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
    Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of cognitive and P50 suppression deficits in chronic patients with schizophrenia.
    Xia L; Wang D; Wang J; Xu H; Huo L; Tian Y; Dai Q; Wei S; Wang W; Zhang G; Du X; Jia Q; Zhu X; Wang L; Tang W; Zhang XY
    Clin Neurophysiol; 2020 Mar; 131(3):725-733. PubMed ID: 32000073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smoking affects the association between cognitive impairment and P50 inhibition defects in patients with chronic schizophrenia: A case-control study.
    Wang DM; Xia LY; Zhou HX; Tian Y; Dai QL; Xiu MH; Chen DC; Wang L; Zhang XY
    Asian J Psychiatr; 2023 Jan; 79():103391. PubMed ID: 36516649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P50 sensory gating, cognitive deficits and depressive symptoms in first-episode antipsychotics-naïve schizophrenia.
    Li S; Yu B; Wang D; Xia L; Wang L; Chen D; Xiu M; Zhang XY
    J Affect Disord; 2023 Mar; 324():153-161. PubMed ID: 36587903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P50 inhibition deficit in patients with chronic schizophrenia: Relationship with cognitive impairment of MATRICS consensus cognitive battery.
    Xia L; Yuan L; Du XD; Wang D; Wang J; Xu H; Huo L; Tian Y; Dai Q; Wei S; Wang W; Trihn TH; Alnatour OI; Chen D; Xiu M; Wang L; Yang M; Zhang XY
    Schizophr Res; 2020 Jan; 215():105-112. PubMed ID: 31780341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of new therapeutic drugs based on the pathophysiology of schizophrenia].
    Hashimoto K
    Seishin Shinkeigaku Zasshi; 2011; 113(4):368-73. PubMed ID: 21702128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tropisetron enhances recognition memory in rats chronically treated with risperidone or quetiapine.
    Poddar I; Callahan PM; Hernandez CM; Yang X; Bartlett MG; Terry AV
    Biochem Pharmacol; 2018 May; 151():180-187. PubMed ID: 29175423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tropisetron improves deficits in auditory P50 suppression in schizophrenia.
    Koike K; Hashimoto K; Takai N; Shimizu E; Komatsu N; Watanabe H; Nakazato M; Okamura N; Stevens KE; Freedman R; Iyo M
    Schizophr Res; 2005 Jul; 76(1):67-72. PubMed ID: 15927799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDP-choline: effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression.
    Knott V; Smith D; de la Salle S; Impey D; Choueiry J; Beaudry E; Smith M; Saghir S; Ilivitsky V; Labelle A
    J Psychopharmacol; 2014 Dec; 28(12):1095-108. PubMed ID: 25315828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation of nicotinic acetylcholine alpha7 receptors rescue schizophrenia-like cognitive impairments in rats.
    Potasiewicz A; Nikiforuk A; Hołuj M; Popik P
    J Psychopharmacol; 2017 Feb; 31(2):260-271. PubMed ID: 28168926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation.
    Kem WR; Olincy A; Johnson L; Harris J; Wagner BD; Buchanan RW; Christians U; Freedman R
    Neuropsychopharmacology; 2018 Feb; 43(3):583-589. PubMed ID: 28825423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tropisetron sensitizes α7 containing nicotinic receptors to low levels of acetylcholine in vitro and improves memory-related task performance in young and aged animals.
    Callahan PM; Bertrand D; Bertrand S; Plagenhoef MR; Terry AV
    Neuropharmacology; 2017 May; 117():422-433. PubMed ID: 28259598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies.
    Lewis AS; van Schalkwyk GI; Bloch MH
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Apr; 75():45-53. PubMed ID: 28065843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of P50 with social function, but not with cognition in patients with first-episode schizophrenia.
    Wang D; Xia L; Zhang Z; Guo J; Tian Y; Zhou H; Xiu M; Chen D; Zhang XY
    Eur Arch Psychiatry Clin Neurosci; 2024 Sep; 274(6):1375-1384. PubMed ID: 37966511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
    Martin LF; Freedman R
    Int Rev Neurobiol; 2007; 78():225-46. PubMed ID: 17349863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.